News
Hiring – Part-time Operations Associate/Executive Assistant
Part-time Operations Associate/Executive AssistantYuhan USA CorporationWork locations: Cambridge, MAEmployee type: part-timeContact Information: yjlee@yuhan-usa.com Yuhan USA Corporation was established in January 2018 as a wholly owned
Yuhan Presents Phase 1b Part 2 Results for Lesigercept – Shows Efficacy in Omalizumab-Refractory Patients
Date: 6/13/25 Yuhan Corporation presented positive Phase 1b Part 2 results for its investigational anti-IgE biologic Lesigercept (YH35324) at the EAACI 2025 Annual Meeting in
Yuhan Corporation Receives $15 Million Milestone from Janssen for Launch of Lazertinib + Amivantamab Combination Therapy in Japan
Yuhan Corporation announced that it will receive a milestone payment of $15 million (approximately 20.7 billion KRW) from Janssen Biotech, a subsidiary of the multinational
Yuhan Presents Preclinical Data on Targeted Therapy YH42946 and Bispecific Immunotherapy YH32364
At the AACR 2025 Annual Meeting, Yuhan Corporation unveiled promising preclinical results for two of its cancer drug candidates: YH42946, a HER2/EGFR tyrosine kinase inhibitor
Yuhan’s HER2×4-1BB Bispecific Antibody YH32367 Shows Early Efficacy and Safety in Phase 1 Solid Tumor Trial
At the AACR 2025 Annual Meeting, Yuhan Corporation presented encouraging interim results from a Phase 1 trial of YH32367, a bispecific antibody targeting HER2 and
Lazertinib + Amivantamab Combo from J&J Posts Strong Q1 Sales, Strengthening Its Position in NSCLC Treatment
Johnson & Johnson (J&J) reported that the combination therapy of Lazertinib (brand name Leclaza in Korea) and Amivantamab (brand name Rybrevant) achieved impressive global sales